Welcome to our dedicated page for Clearpoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on Clearpoint Neuro stock.
ClearPoint Neuro, Inc. develops and commercializes medical-device and therapy-enabling systems for precise navigation to the brain and spine. Its recurring news includes updates on the FDA-cleared and CE-marked ClearPoint Neuro Navigation System, SmartFrame navigation platform, SmartFlow Neuro Cannula, Velocity Alpha MR High Speed Surgical Drill System, and services that support controlled CNS delivery for cell and gene therapy programs.
Company announcements also cover financial results, product clearances and international regulatory approvals, preclinical development services, biopharma and academic partnerships, and integration of the completed IRRAS Holdings acquisition, which expanded the portfolio into neurocritical care and IRRAflow-related products.
ClearPoint Neuro (CLPT) has appointed Danilo D'Alessandro as its new Chief Financial Officer, succeeding Harold Hurwitz, who plans to retire in 2021. D'Alessandro, with extensive experience from Philips, will start as Vice President of Finance on September 29, 2020, and officially assume the CFO role on January 1, 2021. The transition is expected to drive growth and profitability for the company as it aims to expand its global portfolio. ClearPoint's mission is to enhance therapies for complex neurological disorders.
ClearPoint Neuro reported its second quarter financial results for 2020, revealing total revenues of approximately $2.5 million, a 5% decrease year-over-year. The functional neurosurgery revenue dropped 38% to $1.0 million due to COVID-19's impact on elective surgeries. However, biologics and drug delivery revenue surged 183% to $1.2 million, driven by new partnerships. Operating expenses increased 15% to $3.3 million, with an operating loss of $1.5 million. Cash reserves stood at $16.0 million as of June 30, 2020, amid ongoing uncertainty regarding the recovery of elective procedures.
ClearPoint Neuro (Nasdaq: CLPT) plans to release its financial results for Q2 2020 on August 12, 2020, post-market. A conference call will follow at 4:30 p.m. Eastern, where analysts and investors can participate by calling (877) 407-9034. The company's portfolio focuses on advanced neurological therapies, with the ClearPoint Neuro Navigation System actively utilized in 60 clinical sites across the U.S. The firm is navigating uncertainties, including the impacts of COVID-19, but remains committed to its mission of enhancing life quality for patients with neurological disorders.
ClearPoint Neuro reported a 26% year-over-year revenue increase for Q1 2020, reaching approximately $3.1 million, driven by a 169% rise in biologics and drug delivery revenues to $1.0 million. However, functional neurosurgery revenues saw only a 5% increase due to the COVID-19 pandemic, which curtailed elective surgeries. Operating expenses also surged by 33% to $3.4 million. The company withdrew its 2020 revenue forecasts after a significant drop in case volumes, experiencing an 85% reduction in April procedures. Cash reserves stood at $17.0 million as of March 31, 2020.